Henlius Biopharmaceuticals
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leading Chinese biopharma developing and commercializing innovative and biosimilar antibodies for oncology and autoimmune diseases.
OncologyImmunology
Technology Platform
Integrated antibody development and manufacturing platform with proprietary cell line and high-expression technology for monoclonal and bispecific antibodies.
Opportunities
Significant opportunity in global biosimilar market expansion and developing novel combination regimens from its core immuno-oncology assets.
Risk Factors
Pricing pressure on biosimilars and innovative drugs in China, alongside clinical and commercial risks for its novel pipeline in a highly competitive immuno-oncology space.
Competitive Landscape
Faces intense competition from global biologic giants (Roche, Amgen) and a crowded field of domestic Chinese PD-1 developers and biosimilar manufacturers.